- Home
- IMCR vs EH Comparison
IMCR vs EH Comparison
Compare IMCR & EH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCR
- EH
- Stock Information
- Founded
- IMCR 2008
- EH 2014
- Country
- IMCR United Kingdom
- EH China
- Employees
- IMCR N/A
- EH N/A
- Industry
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- EH Military/Government/Technical
- Sector
- IMCR Health Care
- EH Industrials
- Exchange
- IMCR Nasdaq
- EH Nasdaq
- Market Cap
- IMCR 1.5B
- EH 1.2B
- IPO Year
- IMCR 2021
- EH 2019
- Fundamental
- Price
- IMCR $28.40
- EH $18.45
- Analyst Decision
- IMCR Buy
- EH Strong Buy
- Analyst Count
- IMCR 11
- EH 3
- Target Price
- IMCR $59.11
- EH $25.97
- AVG Volume (30 Days)
- IMCR 265.8K
- EH 1.2M
- Earning Date
- IMCR 05-07-2025
- EH 05-19-2025
- Dividend Yield
- IMCR N/A
- EH N/A
- EPS Growth
- IMCR N/A
- EH N/A
- EPS
- IMCR N/A
- EH N/A
- Revenue
- IMCR $333,581,000.00
- EH $62,494,280.00
- Revenue This Year
- IMCR $20.26
- EH $113.39
- Revenue Next Year
- IMCR $8.49
- EH $57.28
- P/E Ratio
- IMCR N/A
- EH N/A
- Revenue Growth
- IMCR 25.75
- EH 288.46
- 52 Week Low
- IMCR $23.15
- EH $10.40
- 52 Week High
- IMCR $62.22
- EH $29.76
- Technical
- Relative Strength Index (RSI)
- IMCR 45.68
- EH 53.89
- Support Level
- IMCR $27.88
- EH $18.38
- Resistance Level
- IMCR $31.38
- EH $19.40
- Average True Range (ATR)
- IMCR 1.60
- EH 0.79
- MACD
- IMCR -0.08
- EH 0.47
- Stochastic Oscillator
- IMCR 22.19
- EH 80.00
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
About EH EHang Holdings Limited ADS
EHang Holdings Ltd is an urban air mobility (UAM) technology platform company. It focuses on making safe, autonomous, eco-friendly air mobility accessible to everyone. EHang provides customers in various industries with unmanned aerial vehicle (UAV) systems and solutions: air mobility (including passenger transportation and logistics), smart city management, and aerial media solutions. EHang's EH216-S has received a production certificate and standard airworthiness certificate for passenger-carrying pilotless eVTOL aircraft issued by the Civil Aviation Administration of China. The group continues to explore the boundaries of the sky to make flying technologies benefit life in smart cities.